2021
|
|

Abstract: Background There are limited data on the neutralizing activity of convalescent plasma (CP) administered in randomized controlled trials (RCT) of COVID‐19 infection. Study Design and Methods As part of an RCT, CP was collected per FDA guidelines from individuals recovered from COVID‐19 infection. CP donors had to have ≥145 optical density (OD) units (ideal target ≥300) using a semiquantitative, immunochromatographic test for IgG antibody to the nucleocapsid protein (NP) … Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
0
9
0

Publication Types

Select...

Relationship

0
0

Authors

Journals